Skip to main content
Erschienen in: Annals of Hematology 4/2012

01.04.2012 | Original Article

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

verfasst von: Pervin Topcuoglu, Mutlu Arat, Muhit Ozcan, Onder Arslan, Osman Ilhan, Meral Beksac, Gunhan Gurman

Erschienen in: Annals of Hematology | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

This retrospective case-matched study evaluated the efficacy of reduced intensity conditioning (RIC) regimen on early and late allogeneic transplant outcome in chronic myeloid leukemia (CML) patients. Twenty-eight patients conditioned with RIC regimen were matched to 56 patients who received a myeloablative conditioning (MAC) regimen. The main criteria for case matching among our CML allotransplant cohort were the Gratwohl scoring system. The median score was 2 (1–4) in each group. The pretransplant disease status was first chronic phase (CP1, n = 20), CP2 (n = 2), and advanced phase (n = 6) in RIC, and CP1 (n = 46), CP2 (n = 3), and advanced phase (n = 7) in MAC. The duration of neutropenia and thrombocytopenia was shorter in RIC than MAC. The grade and duration of mucositis were less in RIC. The need for total parenteral nutrition (21% vs. 77%, p < 0.0001) and febrile neutropenic episodes (50% vs. 95%, p < 0.0001) were observed less frequently in RIC compared with MAC-given patients. Acute or chronic graft versus host diseases (GvHD) were not affected by the intensity of conditioning regimen. The incidence of transplant-related mortality was higher in MAC (7% vs. 14%, p = 0.01). Although more relapse/progression was observed in the RIC group, the probability of 5- and 10-year leukemia-free- and overall survival were similar regardless of conditioning regimen intensity (p > 0.05). In early first CP, the pair of female donor–male recipient and the development of chronic GvHD prolonged both leukemia-free survival and overall survival in multivariate analysis. According to our single-center matched-pair analysis, the use of RIC regimens in patients with low-risk CML results with toxicities less, responses later, and relapses more frequent than the MAC regimens.
Literatur
1.
Zurück zum Zitat Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054–1061. doi:10.1038/leu.2009.38 PubMedCrossRef Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054–1061. doi:10.​1038/​leu.​2009.​38 PubMedCrossRef
3.
Zurück zum Zitat Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562–1568PubMed Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562–1568PubMed
4.
Zurück zum Zitat Slavin S, Nagler A, Naparstek E, Naparstek E, Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMed Slavin S, Nagler A, Naparstek E, Naparstek E, Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMed
5.
Zurück zum Zitat Das M, Saikia TK, Advani SH, Parikh PM, Tawde S (2003) Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 32:125–129. doi:10.1038/sj.bmt.1704107 PubMedCrossRef Das M, Saikia TK, Advani SH, Parikh PM, Tawde S (2003) Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 32:125–129. doi:10.​1038/​sj.​bmt.​1704107 PubMedCrossRef
7.
Zurück zum Zitat Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP (2002) Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant 29:1–8. doi:10.1038/sj/bmt/1703323 PubMedCrossRef Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP (2002) Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant 29:1–8. doi:10.​1038/​sj/​bmt/​1703323 PubMedCrossRef
8.
Zurück zum Zitat Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, Dvorakova D, Lengerova M, Horky O, Koristek Z, Dolezal T, Vorlicek J (2006) Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 38:483–491. doi:10.1038/sj.bmt.1705478 PubMedCrossRef Krejci M, Mayer J, Doubek M, Brychtova Y, Pospisil Z, Racil Z, Dvorakova D, Lengerova M, Horky O, Koristek Z, Dolezal T, Vorlicek J (2006) Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 38:483–491. doi:10.​1038/​sj.​bmt.​1705478 PubMedCrossRef
9.
Zurück zum Zitat Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S, Latin American Cooperative Oncohematology Group (2005) The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 36:1043–1047. doi:10.1038/sj.bmt.1705190 PubMedCrossRef Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S, Latin American Cooperative Oncohematology Group (2005) The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 36:1043–1047. doi:10.​1038/​sj.​bmt.​1705190 PubMedCrossRef
10.
Zurück zum Zitat Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF, Chronic Leukemia Working Party of the EBMT (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969–2976. doi:10.1182/blood-2004-09-3544 PubMedCrossRef Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF, Chronic Leukemia Working Party of the EBMT (2005) Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 106:2969–2976. doi:10.​1182/​blood-2004-09-3544 PubMedCrossRef
11.
Zurück zum Zitat Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H (2001) Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy 3:253–260. doi:10.1080/146532401317070880 PubMedCrossRef Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H (2001) Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Cytotherapy 3:253–260. doi:10.​1080/​1465324013170708​80 PubMedCrossRef
12.
Zurück zum Zitat Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092. doi:10.1016/S0140-6736(98)03030-X PubMedCrossRef Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J, Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092. doi:10.​1016/​S0140-6736(98)03030-X PubMedCrossRef
13.
Zurück zum Zitat Ustün C, Arslan O, Beksaç M, Koç H, Gürman G, Ozçelik T, Yilmaz B, Ilhan O, Akan H, Ozcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek I, Celebi H, Coskun HS (1999) A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 5:28–35, S1083-8791(99)50027-XPubMedCrossRef Ustün C, Arslan O, Beksaç M, Koç H, Gürman G, Ozçelik T, Yilmaz B, Ilhan O, Akan H, Ozcan M, Demirer T, Uysal A, Konuk N, Arat M, Dilek I, Celebi H, Coskun HS (1999) A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: a focus on the incidence of graft-vs.-host disease and relapse. Biol Blood Marrow Transplant 5:28–35, S1083-8791(99)50027-XPubMedCrossRef
14.
Zurück zum Zitat Gürman G, Dilek I, Arslan O, Arat M, Beksaç M, Ilhan O, Ozcan M, Akan H, Dalva K, Konuk N, Uysal A, Koç H (2001) The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. Transfus Apher Sci 24:23–28, S0955-3886(00)00123-5PubMedCrossRef Gürman G, Dilek I, Arslan O, Arat M, Beksaç M, Ilhan O, Ozcan M, Akan H, Dalva K, Konuk N, Uysal A, Koç H (2001) The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. Transfus Apher Sci 24:23–28, S0955-3886(00)00123-5PubMedCrossRef
16.
Zurück zum Zitat Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828PubMed Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828PubMed
17.
Zurück zum Zitat Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259PubMed Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259PubMed
18.
Zurück zum Zitat World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15–22 World Health Organization (1979) Handbook for reporting results of cancer treatment. World Health Organization, Geneva, pp 15–22
20.
Zurück zum Zitat Kantarjian H, O’Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837–845. doi:10.1002/cncr.23238 PubMedCrossRef Kantarjian H, O’Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837–845. doi:10.​1002/​cncr.​23238 PubMedCrossRef
21.
Zurück zum Zitat Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7:473–485, S1083-8791(01)50035-XPubMedCrossRef Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 7:473–485, S1083-8791(01)50035-XPubMedCrossRef
22.
Zurück zum Zitat Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
23.
Zurück zum Zitat Mantel N (1996) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170 Mantel N (1996) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170
24.
Zurück zum Zitat Cox DR (1072) Regression models and life tables. J Roy Stat Soc B 34:187–220 Cox DR (1072) Regression models and life tables. J Roy Stat Soc B 34:187–220
25.
Zurück zum Zitat Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513–521PubMed Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D (2006) Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91:513–521PubMed
26.
Zurück zum Zitat Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512–520, S1083-8791(02)50012-4PubMedCrossRef Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Storb R (2002) Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 8:512–520, S1083-8791(02)50012-4PubMedCrossRef
27.
28.
Zurück zum Zitat Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D (2003) Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168–2177PubMedCrossRef Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L, Choufi B, Bilger K, Tournilhac O, Vey N, Stoppa AM, Coso D, Gastaut JA, Viens P, Maraninchi D, Olive D, Blaise D (2003) Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 17:2168–2177PubMedCrossRef
29.
Zurück zum Zitat Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978–1985. doi:10.1182/blood.V99.6.1978 PubMedCrossRef Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, Chauncey T, McSweeney PA, Little MT, Corey L, Storb R (2002) Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99:1978–1985. doi:10.​1182/​blood.​V99.​6.​1978 PubMedCrossRef
31.
Zurück zum Zitat Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91:2581–2587PubMed Yu C, Seidel K, Nash RA, Deeg HJ, Sandmaier BM, Barsoukov A, Santos E, Storb R (1998) Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91:2581–2587PubMed
32.
Zurück zum Zitat Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L, Ringden O, Winiarski J, Ljungman P, Dalianis T (2006) The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91:401–404PubMed Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn BM, Barkholt L, Ringden O, Winiarski J, Ljungman P, Dalianis T (2006) The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica 91:401–404PubMed
33.
Zurück zum Zitat Carreras E, Bertz H, Arcese W, Vernant JP, Tomás JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92:3599–3604PubMed Carreras E, Bertz H, Arcese W, Vernant JP, Tomás JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Di Girolamo G, Demuynck H, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben-Bassat I, Koza V, Gratwohl A, Apperley JF (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92:3599–3604PubMed
34.
Zurück zum Zitat Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, Mufti GJ (2006) Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 38:823–824. doi:10.1038/sj.bmt.1705528 PubMedCrossRef Ramasamy K, Lim ZY, Pagliuca A, Grundy R, Devereux S, Ho AY, Mufti GJ (2006) Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant 38:823–824. doi:10.​1038/​sj.​bmt.​1705528 PubMedCrossRef
35.
Zurück zum Zitat Kim I, Lee KH, Choi Y, Keam B, Koo NH, Yoon SS, Yoo KY, Park S, Kim BK (2007) Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci 22:227–234. doi:10.3346/jkms.2007.22.2.227 PubMedCrossRef Kim I, Lee KH, Choi Y, Keam B, Koo NH, Yoon SS, Yoo KY, Park S, Kim BK (2007) Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning. J Korean Med Sci 22:227–234. doi:10.​3346/​jkms.​2007.​22.​2.​227 PubMedCrossRef
36.
Zurück zum Zitat Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMed Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMed
37.
Zurück zum Zitat Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barret AJ (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36:1009–1015. doi:10.1038/sj.bmt.1705167 PubMedCrossRef Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barret AJ (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36:1009–1015. doi:10.​1038/​sj.​bmt.​1705167 PubMedCrossRef
38.
Zurück zum Zitat Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ (2006) A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91:663–666PubMed Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ (2006) A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 91:663–666PubMed
39.
Zurück zum Zitat Bozdag SC, Soydan EA, Topçuoglu P, Bilgin AU, Bakanay SM, Koc H, Beksac M, Ilhan O, Ozcan M, Gurman G, Arat M (2007) Treatment of relapse after allogeneic stem cell transplantation in CML patients: imatinib only versus imatinib & DLI. Bone Marrow Transplant 39(suppl 1):S70–S71. doi:10.1038/sj.bmt.1705631, meeting abstract Bozdag SC, Soydan EA, Topçuoglu P, Bilgin AU, Bakanay SM, Koc H, Beksac M, Ilhan O, Ozcan M, Gurman G, Arat M (2007) Treatment of relapse after allogeneic stem cell transplantation in CML patients: imatinib only versus imatinib & DLI. Bone Marrow Transplant 39(suppl 1):S70–S71. doi:10.​1038/​sj.​bmt.​1705631, meeting abstract
40.
Zurück zum Zitat Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM (2005) Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19:990–997. doi:10.1038/sj.leu.2403730 PubMedCrossRef Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM (2005) Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 19:990–997. doi:10.​1038/​sj.​leu.​2403730 PubMedCrossRef
41.
Zurück zum Zitat Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445. doi:10.1182/blood-2002-02-0535 PubMedCrossRef Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445. doi:10.​1182/​blood-2002-02-0535 PubMedCrossRef
42.
Zurück zum Zitat Sala-Torra O, Martin PJ, Storer B, Traina F, Sorror ML, Storb R, Sandmaier BM, Flowers ME (2008) Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 41:887–893. doi:10.1038/sj.bmt.1705987 PubMedCrossRef Sala-Torra O, Martin PJ, Storer B, Traina F, Sorror ML, Storb R, Sandmaier BM, Flowers ME (2008) Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant 41:887–893. doi:10.​1038/​sj.​bmt.​1705987 PubMedCrossRef
43.
Zurück zum Zitat Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ (2007) Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 48:295–301. doi:10.1080/10428190601078464 PubMedCrossRef Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ (2007) Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma 48:295–301. doi:10.​1080/​1042819060107846​4 PubMedCrossRef
44.
Zurück zum Zitat Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM (2010) Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20):4018–4020. doi:10.1182/blood-2010-01-263624 PubMedCrossRef Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RM (2010) Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20):4018–4020. doi:10.​1182/​blood-2010-01-263624 PubMedCrossRef
45.
Zurück zum Zitat Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R, German CML Study Group (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885. doi:10.1182/blood-2009-08-237115 PubMedCrossRef Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R, German CML Study Group (2010) Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115(10):1880–1885. doi:10.​1182/​blood-2009-08-237115 PubMedCrossRef
Metadaten
Titel
Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients
verfasst von
Pervin Topcuoglu
Mutlu Arat
Muhit Ozcan
Onder Arslan
Osman Ilhan
Meral Beksac
Gunhan Gurman
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Hematology / Ausgabe 4/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1349-2

Weitere Artikel der Ausgabe 4/2012

Annals of Hematology 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.